Year: 2020

(Bloomberg) — The recent rally in Tesla Inc. shares after the company reported record quarterly deliveries shows that investors are growing more optimistic on the company as it proves it can walk the walk, according to analysts.The electric carmaker’s fourth quarter deliveries of 112,000 units topped Street expectations, defying skeptics by hitting its 2019 delivery guidance. Tesla delivered 367,500 vehicles total in 2019, beating the low end of its forecast for at least 360,000.Shares in Tesla rose as much as 5.5% on Friday. Still, the upbeat delivery numbers haven’t been enough to encourage some analysts to turn bullish on the …read more […]

The cannabis sector has run into major liquidity issues with the lack of access to the banking system in the U.S. and market issues in Canada. In the process, the market has seen a substantial decline in mergers with a shift in deals towards stock-for-stock ones. Several companies set to close big U.S. deals could stand out in a sector where competitors can’t merge to compete on scale.According to Viridian Capital Advisors, the cannabis sector ended 2019 at a crawl. Capital raises were near non-existent with only 2 for the week ending December 13 and no M&A activity during the …read more […]

Q3 2019 Catalyst Pharmaceuticals Inc Earnings Call …read more […]

There was plenty of turmoil in sports business in 2019. Here are a few storylines to watch in 2020, from gambling to streaming to NCAA rules. …read more […]

Today we’ll look at McGrath RentCorp (NASDAQ:MGRC) and reflect on its potential as an investment. Specifically, we’re… …read more […]

Novartis AG, Merck & Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the price increases are below 10%, with the median price increase around 5%, according to 3 Axis. Swiss drugmaker Novartis raised prices on nearly 30 drugs including psoriasis treatment Cosentyx and multiple sclerosis medicine Gilenya, 3 Axis said. …read more […]

Investors shouldn’t worry about a full-fledged war with Iran. But there will still be bloodshed. …read more […]

MetLife, Inc. (NYSE:MET) saw a decent share price growth in the teens level on the NYSE over the last few months. With… …read more […]

Multiple factors make this an opportune time to buy into the stock Continue reading… …read more […]

Investments that pay a return on a fixed schedule. With the Federal Reserve’s decision to leave interest rates unchanged and rates seemingly to remain low for now, fixed-income market watchers are reviewing … …read more […]